Topic: multiple sclerosis
Just two days after Mylan won FDA approval for its long-acting Copaxone generic, Mylan’s European partner got a green light, too.
Mylan’s long been frustrated by generics delays. But on Tuesday evening, it picked up an approval for one of them—and it came at Teva’s expense.
Rep. Elijah Cummings, D-Md., is urging President Trump to press for lower prices on Biogen's multiple sclerosis drug Zinbryta.
Merck KGaA has won European approval for its oral MS drug, but competing with more established rivals won't be easy.
Novartis has launched plenty of large-scale multiple sclerosis studies. But its newest one is different, thanks to a purpose-built smartphone app.
Biogen and AbbVie’s MS drug Zinbryta faces new restrictions in Europe at a time when tough payers and new challengers are roiling the field.
The positive data for Roche’s Ocrevus keep on coming.
Roche’s new drug Ocrevus has landed in the same sentence with the three letters all makers of multiple sclerosis drugs dread: PML.
Some closely watched new drugs grabbed the spotlight at the American Academy of Neurology meeting this week, and plenty of other therapies put up results worth noting.